C4X Discovery to receive $13m milestone under AZN NRF2 license
C4X Discovery Holdings says it will receive a $13 million milestone payment from AstraZeneca after an oral NRF2 activator programme enters the clinic under its exclusive worldwide license agreement.
4 September 2026 — C4X Discovery Holdings Ltd (“C4XD”), a pioneering Drug Discovery company, today announces that it will receive a $13 million milestone payment from AstraZeneca [LON: AZN], triggered by the entry of the oral NRF2 activator programme into the clinic.Under the terms of the licensing…